Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse til evaluering af effektiviteten af to doser AP-472 som supplement til levodopa hos deltagere med Parkinsons sygdom (PD) med motoriske udsving

26. oktober 2026 opdateret af: Appello Pharmaceuticals, Inc.

Fase 2, dobbeltblind, placebo-kontrolleret undersøgelse for at evaluere effektiviteten af to doser AP-472 som adjuvans til levodopa hos deltagere med Parkinsons sygdom (PD) med motoriske fluktuationer

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.

The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

150

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72205-5551
        • Rekruttering
        • University of Arkansas for Medical Sciences (Site #208)
    • California
      • Carlsbad, California, Forenede Stater, 92011
        • Rekruttering
        • Profound Research LLC (Site #222)
      • Los Alamitos, California, Forenede Stater, 90720-3108
        • Rekruttering
        • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
      • Los Angeles, California, Forenede Stater, 90033-5310
        • Rekruttering
        • Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
      • Palo Alto, California, Forenede Stater, 94301
        • Rekruttering
        • Parkinson's Research Centers of America (Site #218)
    • Colorado
      • Englewood, Colorado, Forenede Stater, 80113-2776
        • Rekruttering
        • Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33486
        • Rekruttering
        • Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
      • Boca Raton, Florida, Forenede Stater, 33486
        • Rekruttering
        • UM-UHealth at Boca Raton (Site #226)
      • Hallandale, Florida, Forenede Stater, 33009
        • Rekruttering
        • Velocity Clinical Research - Hallandale Beach (Site #228)
      • Miami, Florida, Forenede Stater, 33136-1051
        • Rekruttering
        • University of Miami (Site #220)
      • Orlando, Florida, Forenede Stater, 32825
        • Rekruttering
        • Neurology One (Site #205)
      • Tampa, Florida, Forenede Stater, 33613-4808
        • Rekruttering
        • USF Parkinson's Disease and Movement Disorders Center (Site #206)
    • Georgia
      • Augusta, Georgia, Forenede Stater, 30912-0020
        • Rekruttering
        • Augusta University Medical Center (Site #212)
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46256
        • Rekruttering
        • Josephson Wallack Munshower Neurology PC (Site #231)
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • The University of Kansas (KU) (Site #216)
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536-0001
        • Rekruttering
        • Kentucky Neuroscience Institute (Site #213)
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215-5400
        • Rekruttering
        • Beth Israel Deaconess Medical Center (Site #211)
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan Health System (UMHS) (Site #202)
      • Farmington Hills, Michigan, Forenede Stater, 48334-2973
        • Rekruttering
        • Quest Research Institute - Alcanza - PPDS (Site #201)
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • Rekruttering
        • University of New Mexico Health Sciences Center (Site #225)
    • New York
      • New York, New York, Forenede Stater, 10029-6501
        • Rekruttering
        • Mount Sinai School of Medicine (Site #209)
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Joan and Sanford I. Weill Department of Medicine (Site #224)
    • North Carolina
      • Asheville, North Carolina, Forenede Stater, 28806
        • Rekruttering
        • Asheville Neurology Specialists, P.A. (Site #229)
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Duke Neurological Disorders Clinic (Site #210)
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195-0001
        • Rekruttering
        • Cleveland Clinic (Site #223)
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The Ohio State University Wexner Medical Center (site #207)
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center (Site #204)
    • Texas
      • Cypress, Texas, Forenede Stater, 77429
        • Rekruttering
        • Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
      • Round Rock, Texas, Forenede Stater, 78681-3578
        • Rekruttering
        • Central Texas Neurology Consultants (Site #203)
    • Washington
      • Kirkland, Washington, Forenede Stater, 98034-3013
        • Rekruttering
        • EvergreenHealth (Site #219)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

30 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

Participants must meet all of the following criteria to take part in the study:

  1. Be a man or woman between 30 and 80 years of age at the time of screening.
  2. Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
  3. Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
  4. Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
  5. Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
  6. Be able to walk independently, with or without the use of a walking aid.
  7. Be able to swallow oral medication.
  8. Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
  9. Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).

Key Exclusion Criteria:

Participants cannot take part in the study if any of the following apply:

  1. Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
  2. Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
  3. Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
  4. Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
  5. Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
  6. Routinely use on-demand "rescue" Parkinson's medications more than three times per week.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Oral tablet

Eksperimentel: Low Dose

AP-472 100 mg per day

Oral tablet

Oral tablet

Eksperimentel: High Dose

AP-472 300 mg per day

Oral tablet

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Ændring fra baseline i gennemsnitlig daglig OFF-tid på motordagbøger for AP-472 sammenlignet med placebo (normaliseret til 16 timers vågentid)
Tidsramme: Uge 12
Uge 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring fra baseline i ON-tid uden generende dyskinesi (normaliseret til 16 timer)
Tidsramme: Uge 12
Uge 12
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
Tidsramme: Week 12

For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better.

Week 12
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
Tidsramme: Week 12

For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better.

Week 12
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
Tidsramme: Week 12

The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better.

Week 12
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Tidsramme: Week 12

The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better.

Week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. februar 2026

Primær færdiggørelse (Anslået)

3. september 2027

Studieafslutning (Anslået)

3. januar 2028

Datoer for studieregistrering

Først indsendt

29. januar 2026

Først indsendt, der opfyldte QC-kriterier

19. februar 2026

Først opslået (Faktiske)

25. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner